NCT00551629View on ClinicalTrials.gov

A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)

PHASE2CompletedINTERVENTIONAL
Enrollment

708

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions
Bacterial Infections; Virus Diseases
Interventions
BIOLOGICAL

AR51 (12, 10)

vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg

BIOLOGICAL

PR51 (3, 10)

vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg

BIOLOGICAL

PR51 (6, 10)

vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg

BIOLOGICAL

PR51 (6, 15)

vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00551629 - A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002) | Biotech Hunter | Biotech Hunter